People who have been trying their luck to get rid of a migraine with the help of all the possible treatments available in the market but are still exhausted with the pain and suffering can find relief with the new medication according to the preliminary studies that have been released on Tuesday.
The new class of drugs that have been added to the list of treating migraine is Erunumab. It is entirely human monoclonal antibodies that can block the calcitonin gene-related peptide that transfers the signals of migraine pain during an attack. This medication is a long-lasting injection that can help the migraine attack to stop from starting.
Dr. David Kudrow, the director of the California medical clinic for a headache said, “If the CGRP can be blocked, then it is possible to abort the migraine attack.”
About thirty-seven million American people have a migraine troubling them according to the American headache society. Out of these, approximately 4 million people have the chronic form of migraine and have the suffering last for about 10-14 days maximum.
Some people get relief from the cost-effective, over-the-counter drugs like ibuprofen whereas; others require stronger medication medications, like sumatriptan and ergotamine that help in the constriction of blood vessels in the brain and can also cause dizziness. Some people even take the help of Botox injections to get relief from the migraine attacks. But, almost half or more than that of all the sufferers do not get any proper treatment for migraine pain.
Dr. Peter Goadsby, the professor in chief of neurology at kings college London, UK, and the University of California, San Francisco said, “this is certainly the very first ever mechanism specific migraine drug designed for prevention. This will change the treatment of a migraine for those who do not respond to the conventional treatments.”